Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· October 20, 2026

Zions projects 8%-12% Q3 2027 net interest income growth while scaling Basis multifamily to $30M-$40M medium-term revenue

View original at seekingalpha.com
“"net earnings available to common was $262 million or $1.78 per share" (Chairman & CEO Harris Simmons)”
Verbatim excerpt from the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Loan growth expected at 2%-4% for Q3 2027 vs Q3 2026; outlook tempered, particularly in commercial real estate.

    60% confidence
  • Cash-flow hedges are kept under 2 years and rolled on a continuous basis.

    60% confidence
  • Q3 deposit growth was a little uneven and may not persist at 8.8% annualized; the Basis expense outlook beyond 2027 awaits more experience.

    60% confidence
  • Q3 2027 adjusted customer-related fee income expected to grow 6%-9% from $182M in Q3 2026.

    60% confidence
  • Analysts commended the new quantitative guidance ranges.

    60% confidence
  • Texas M&A disruption is an opportunity for Zions and is viewed as more positive.

    60% confidence
  • Over the medium term Basis is expected to generate approximately $30M-$40M of annual revenue; 2027 revenue $17M-$20M and expense $12M-$13M.

    60% confidence
  • Buyback actions are subject to regulatory approvals and the Board, but there are scenarios where capital absorption could increase.

    60% confidence
  • Q3 2027 adjusted noninterest expense expected to increase approximately 4%-6%.

    60% confidence
  • CRE showed basically no growth in the quarter (negative $9M), mainly due to Amegy being down; management is not especially worried.

    60% confidence
  • CRE pipeline is pretty good but Zions is being very disciplined in underwriting amid competition and rates.

    60% confidence
  • Management is reasonably pleased with Q3 results: net earnings to common $262M or $1.78/share, NIM 3.23%, credit losses 2 bps annualized.

    60% confidence
  • Guidance implies deposit costs up about 40 bps (beta in the upper 40s to low 50s), with NIM scenarios in the mid-3s in 2027.

    60% confidence
  • 2026 operating leverage is now expected at approximately 40-50 bps including Basis, versus 100-150 bps previously; excluding the acquisition it would approach the low end of the prior range.

    60% confidence
  • Expects better Q4 Basis revenue than Q3, and describes the effort as a marathon rather than a sprint.

    60% confidence
  • Wealth management is a compelling growth opportunity; Wealth Select expands the addressable market to $100K-$1M investable assets.

    60% confidence
  • Q3 2027 NII is expected to increase approximately 8%-12%, assuming three rate increases and deposit costs rising to around 2%.

    60% confidence
  • Total cost of deposits increased 11 bps to 1.59%; a presentation change added ~3 bps to reported cost of deposits with no impact on overall cost of funds.

    60% confidence
  • About $2.2 billion of broker deposits mature in Q4; excess money markets can fund loans or reduce broker deposits.

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com